A strong consulting professional with the Doctor of Medicine and Master of Science from Columbia University. Experienced in biotechnology research analysis with a demonstrated history of working in the healthcare field and the pharmaceuticals industry.
Our approach is based on a new investment philosophy, “Integrated BioSci Investing,” which takes roots in both value/growth that are adapted specifically for bioscience stocks. Our analytical research is powered by the integration of (medical, scientific, and market) expertise to deliver an unprecedented accuracy in clinical trial forecasting that, in and of itself, is one of the requisites to finding alpha bioscience investment. Ultimately, our tireless due diligence and the wisdom of IBI members translate into strong returns for all. To name a couple winners, Nektar Therapeutics, Spectrum Pharmaceuticals, Madrigal Pharmaceuticals, Atara Biotherapeutics, and Crispr Therapeutics, correspondingly delivered +258%, +174%, +180%, +186%, and +173% for our subscribers.
less
